Staphylococcal Innate Immune Evasion

In a relatively short period of time we and others have identified an impressive amount of highly specific innate immune evasion molecules in a single micro-organism. Probably this is 

Work described in this chapter was made possible by grants from STW ( UKG-06609), EU FP6 (STREP 512093) (TOK 5I7128), NGI( 050-71-028),NWO ( 91206020) and the Vanderes foundation ( 156). 

Shcn L. Plasmid analysis and phage typing in the study of staphylococcal colonization and disease in newborn infants. Chin Med Sci J 1993s 8 157-161. 

Perl TM, Golub JE. New approaches to reduce Staphylococcus aureus nosocomial in cdon rates treating S. aureus nasal carriage. Ann Pharmacother 1998 32 57-16. 

Kluytmans J, van Belkum A, Verbrugh H. Nasal carriage of Staphylococcus aureus epidemiology, underlying mechanisms and associated risks. Clin Microbiol Rev 1997 10 505-520. 

---

Figure2. Staphylococcal innate immune evasion. The molecules produced by S-aureusthatcounteract the different steps of our innate immune system. SSL-5 (Staphylococcal Superantigen-like 5), Eap (Extracellular adherence protein), CHIPS (Chemotaxis inhibitory protein of Staphylococci), FLIPr (FPRL-1 inhibitory protein), SSL-7 (Staphylococcal Superantigen-like 7), Efb (Extracellular fibrinogen binding protein), Ecb(Extracellularcomplementbindingprotein), protA(protein A), SCI Nl (Staphylococcal Complement inhibitor), SCIN B (Staphylococcal Complementinhibitor-B), SCIN C (Staphylococcal Complement inhibitor-C), SAK (Staphylokinase).

Rooijakkers SH, van Kessel KP, van Strijp JA. Staphylococcal innate immune Evasion. Trends Microbiol 2005 13 596-601. 

---